| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H22O5 |
| Molecular Weight | 366.4071 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(C=C2CCCC(=CC3=CC=C(O)C(OC)=C3)C2=O)=CC=C1O
InChI
InChIKey=DHKKONBXGAAFTB-OTYYAQKOSA-N
InChI=1S/C22H22O5/c1-26-20-12-14(6-8-18(20)23)10-16-4-3-5-17(22(16)25)11-15-7-9-19(24)21(13-15)27-2/h6-13,23-24H,3-5H2,1-2H3/b16-10+,17-11+
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Tox targets
PubMed
Patents
Sample Use Guides
Oral. First 2 days of therapy in a daily dose of 300 mg, then - 400 mg. Multiplicity of admission - 3-4 r / day. The course of treatment is 3-4 weeks.
Route of Administration:
Oral
For these studies the LNCaP and PC-3 human prostate cancer cell lines were obtained from ATC. These cells were maintained in RPMI (LNCaP cells) or DMEM-S12 (PC-3 cells) media containing 10% fetal calf serum and 1% penicillinstreptomycin. To assess BMHPC (Cyclovalone) effects on cell proliferation, LNCaP or PC-3 cells were seeded in 24-well plates (5,000 cells/well) containing 1.0 ml of RPMI (LNCaP cells) or DMEM-S12 medium and allowed to attach for 72 h. Following attachment (day 0), the medium was replaced with fresh medium and the cells were treated with 5 fil of ethanol (controls) or BMHPC (0.2-10 mkg/ml tissue culture medium) added in 5 mkl absolute ethanol. The cells were grown in the presence of BMHPC for 2-9 days and medium and the drug were replaced every 48 h. Cell number was determined by hemocytometer counts at the times indicated in the text and figure legends and DNA content per well was determined by the Burton assay
ACTIVE MOIETY
